Skip to main content
Chronic Kidney Disease Patient Daniel)

CSL Vifor: Managed Access Programs

Pictured: Chronic Kidney Patient Daniel

CSL Vifor: Managed Access Programs

HAE Patient Machelle Pecoraro and son

CSL Vifor supports efforts to provide early access of investigational drugs for patients facing serious illnesses who have exhausted all available treatment options (unmet medical needs). Where possible, the use of an investigational drug as part of a clinical trial is preferable because clinical trials follow strict scientific standards, are conducted in a well-controlled environment, designed to produce reliable data and results which can allow us to obtain the regulatory approvals in order to provide access to these treatments to more patients.

Information about ongoing clinical trials evaluating CSL Vifor investigational drugs can be found at

In circumstances where patients have exhausted approved treatment options and are not eligible for clinical trials, CSL Vifor supports early access to investigational drugs via Managed Access Programs which describe how healthcare professionals can submit requests for access to investigational drugs on behalf of the patients in their care.

It’s important to remember that investigational drugs have not yet received regulatory approval; therefore, their potential risks and benefits are not yet established. Healthcare professionals and patients should consider all possible benefits and risks when seeking access to an investigational drug under the Managed Access Program.

CSL Vifor may also provide access to Managed Access Programs for patients with unmet medical needs in countries where our drugs have obtained regulatory approval but are not yet commercially available.

CSL Vifor experts will review each request according to CSL Vifor procedures. The final decision is based on balancing several factors, including, but not limited to: regulatory considerations, strength of the clinical data, benefit-risk profile, the impact on clinical development program, the phase of development and probability and timing of regulatory approval, availability and sustainability of investigational drug supply. In addition to CSL Vifor procedures, all requests are also subject to regulatory requirements and laws of the country where the request originates.

Make a Request
Requests for investigational or commercially unavailable products through a Managed Access Program can only be made by the treating physician of the patient. To make the request, the treating physicians can click on this link “MAP Request Form

CSL Vifor Current Managed Access Programs

Indication   Program Further information & access availability
Chronic kidney disease-associated pruritus   Difelikefalin Managed Access Program Contact:
Severe, active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) in combination with a rituximab or cyclophosphamide regime   Avacopan Managed Access Program Contact:
Immunoglobulin A nephropathy (IgAN)   Sparsentan Managed Access Program Contact: